Benedetta Imperiali

Dr. Benedetta Imperiali

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMManuela Montanaro
Manuela Montanaro
MAMassimiliano Agostini
Massimiliano Agostini
LAlucia Anemona
lucia Anemona
Elena BonannoElena Bonanno
Elena Bonanno
FSFrancesca Servadei
Francesca Servadei
Manuel ScimecaManuel Scimeca
Manuel Scimeca
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.

5 October 2026 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
KCKian Cotton
Kian Cotton
CEChristopher Edwards
Christopher Edwards
OPOurania Papapanagiotou
Ourania Papapanagiotou
ASArtem Smirnov
Artem Smirnov
ECEleonora Candi
Eleonora Candi
MNMaria Niklison-Chirou
Maria Niklison-Chirou
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.